Celyad Oncology Provides Fourth Quarter 2023 Business Update and 2024 Outlook

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Celyad Oncology (Euronext: CYAD) (the “Company”), today provides a fourth quarter 2023 business update and an outlook for 2024. Michel Lussier, interim Chief Executive Officer of Celyad Oncology, commented: “2023 has been a very important year for Celyad Oncology, after the changes that occurred in 2022. Our research team has made a remarkable progress to broaden the range of cancer indications that could be targeted by chimeric antigen receptor (CA